🇺🇸 FDA
Patent

US 10654842

Dopamine D3 receptor antagonist compounds

granted A61PA61P25/12A61P25/18

Quick answer

US patent 10654842 (Dopamine D3 receptor antagonist compounds) held by Indivior UK Limited expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Indivior UK Limited
Grant date
Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P25/12, A61P25/18, A61P25/30, A61P43/00